Digital medical services platform Teladoc Health (NYSE:TDOC) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 2.2% year on year to $626.4 million. The company expects next quarter’s revenue to be around $637 million, close to analysts’ estimates. Its GAAP loss of $0.28 per share was 9.2% below analysts’ consensus estimates.
Is now the time to buy TDOC? Find out in our full research report (it’s free for active Edge members).
Teladoc (TDOC) Q3 CY2025 Highlights:
- Revenue: $626.4 million vs analyst estimates of $625.8 million (2.2% year-on-year decline, in line)
- EPS (GAAP): -$0.28 vs analyst expectations of -$0.26 (9.2% miss)
- Adjusted EBITDA: $69.91 million vs analyst estimates of $64.95 million (11.2% margin, 7.6% beat)
- Revenue Guidance for Q4 CY2025 is $637 million at the midpoint, roughly in line with what analysts were expecting
- EPS (GAAP) guidance for the full year is -$1.18 at the midpoint, missing analyst estimates by 14.3%
- EBITDA guidance for the full year is $278.5 million at the midpoint, above analyst estimates of $274.2 million
- Operating Margin: -8.3%, down from -6.9% in the same quarter last year
- Market Capitalization: $1.45 billion
StockStory’s Take
Teladoc’s third quarter results were met with a negative market reaction, as revenue landed in line with Wall Street’s expectations but continued to decline year-over-year. Management attributed the performance to ongoing challenges in its U.S. direct-to-consumer mental health segment and a mix shift towards visit-based revenues. CEO Charles Divita highlighted the company’s efforts to enhance product offerings and drive greater engagement across its integrated care and mental health platforms. He stated, "We know that we have important work ahead of us," acknowledging that pressures on affordability and rising costs remain substantial across the healthcare landscape.
Looking ahead, Teladoc’s guidance is shaped by a strategic pivot toward insurance-based mental health offerings and continued investment in product innovation. Management expects the ramp-up of the BetterHelp insurance rollout and international expansion to gradually offset U.S. cash pay headwinds. CFO Mala Murthy cautioned that, while early signs of the insurance rollout are promising, "the economics you see and the margins you see today are almost entirely cash pay" and improvements will take time. The company is also focused on cost discipline and operational streamlining as it works to restore profitability.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to a combination of innovation in integrated care, ongoing challenges in U.S. mental health, and a deliberate focus on operational efficiency.
- Integrated care innovation: Teladoc launched enhancements to its Prism care delivery platform, enabling providers to address gaps in care more effectively and facilitating provider-to-provider consults. This is expected to improve care outcomes and increase engagement points for members.
- BetterHelp insurance rollout: The company expanded BetterHelp’s insurance-based offering to seven states and Washington, D.C., following the UpLift acquisition. Initial conversion rates and user engagement metrics are meeting management’s expectations, but the insurance business is still a small share of total BetterHelp revenue.
- International growth momentum: Teladoc’s international integrated care segment delivered double-digit constant currency revenue growth, aided by the acquisition of Australia’s Telecare. Management sees further opportunity to penetrate public health sectors abroad.
- Operational efficiency and cost control: The company reported improvements in technology, development, and general administrative expenses, supported by hiring deferrals and targeted cost-saving initiatives. Free cash flow increased sequentially, and the balance sheet remains strong.
- Leadership transition: CFO Mala Murthy will be stepping down after six years. Management credited her with shaping Teladoc’s financial strategy during a period of transformation, while reiterating a commitment to ongoing cost discipline and strategic investment.
Drivers of Future Performance
Management’s outlook is anchored by the transition to insurance-based mental health, ongoing product enhancements, and international expansion, but acknowledges persistent margin pressures and competitive headwinds.
- Insurance model ramp-up: Teladoc expects BetterHelp’s insurance rollout to drive user growth and improve long-term profitability, though margins may remain volatile as the transition progresses. Management noted that insurance could lead to lower customer acquisition costs, but near-term economics are still dominated by the cash pay business.
- Integrated care engagement: The company is investing in new clinical intervention models and connected devices for chronic care, aiming to increase per-member engagement and demonstrate greater value to clients. Product innovations are positioned as essential to winning new contracts and expanding existing relationships, especially in employer channels.
- Competitive landscape and cost risks: Management highlighted increasing competition in U.S. mental health, particularly as more competitors offer insurance reimbursement. Tariff-related headwinds and the need for ongoing technology investment remain risks to margin expansion and overall profitability.
Catalysts in Upcoming Quarters
In the coming quarters, our team will be monitoring (1) the pace and effectiveness of BetterHelp’s insurance rollout and its impact on user growth, (2) adoption and revenue contribution from new integrated care products and chronic care interventions, and (3) continued international expansion, particularly in Australia and other key markets. Progress on cost containment and further product innovation will also be crucial for Teladoc’s profitability trajectory.
Teladoc currently trades at $7.95, down from $8.22 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
High Quality Stocks for All Market Conditions
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.